Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

ct of 1995, including statements about the timing of the announcement of the results of clinical trials for our proprietary and our partnered programs, the timing of the completion or initiation of further development of our wholly-owned and our partnered programs, expectations that events will occur that will result in greater value for the Company, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our ability to partner our proprietary drug candidates for up-front fees, milestone and/or royalty payments, our future plans to progress and develop our proprietary programs and the plans of our collaborators to progress and develop programs we have licensed to them, and our plans to build a late-stage development company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array BioPharma Inc. to meet objectives tied to milestones and royalties; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks ass
'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... HCL information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:10/30/2014)... Ottawa, Ontario (PRWEB) October 30, 2014 ... the Spartan RX CYP2C19 System . It detects ... a non-invasive cheek swab. , The Spartan RX CYP2C19 ... medicine that has been approved in Canada. Due to ... that it may be used by healthcare professionals such ...
(Date:10/30/2014)... 30, 2014 A new report, commissioned by ... takes an in-depth look at Indiana,s ... resulted over two different time frames: 1993 to 2002 ... of future opportunities for investment growth.  The Life ... report shows gains in innovation dollars as well as ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear ... (Primary & Secondary), and End-User (Transmission & Distribution, ... Generation) - Trends and Forecasts to 2019”, defines ... forecasting of the market size. , Browse more ... spread through 146 Pages and in-depth TOC on ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... 2, 2011 Spectros Corporation announced today an expansion ... the signing of 3 new distributors based in Korea, ... selling Spectros products outside of the U.S. ... opportunity offered by the superior performance of the T-Stat® ...
... one heartbeat. That,s what is needed for a new, ... source in the heart of a dangerous cardiac arrhythmia called ... of the heart, which, if ignored, can lead to ventricular ... in the United States alone. The technique, developed by ...
... , Porphyrins are organic molecules that appear in the ... and have a metal atom ,at their center that ... ,in the field of molecular electronics lies in their ... explains the responsible of the work at the Nanomaterials ...
Cached Biology Technology:Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark 2Dangerous arrhythmia analyzed in a heartbeat 2Dangerous arrhythmia analyzed in a heartbeat 3Dangerous arrhythmia analyzed in a heartbeat 4The quantum tunneling effect leads electron transport in porphyrins 2
(Date:10/28/2014)... in German . ... acquire sufficient food when times are lean? By studying ... d,Ivoire researchers of the Max Planck Institute for Evolutionary ... how great apes can acquire extra energy needed to ... their sleeping nests more en route to breakfast sites ...
(Date:10/28/2014)... to expand the Office of Rare Diseases Research ... Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research Network ... 22 consortia will work with 98 patient advocacy ... treatments for patients with rare diseases. The collaborations ... 2014 funding from NIH. , Rett syndrome, MECP2 ...
(Date:10/28/2014)... differences in moving activity in a novel environment ... angling, according to an experimental study completed at ... Game and Fisheries Research Institute. The study used ... and authentic angling trials to analyse if behaviours ... reared in traditional and enriched hatchery rearing environments. ...
Breaking Biology News(10 mins):The early chimp gets the fig 2The early chimp gets the fig 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2
... LANSING, Mich. With millions of newborns, blood samples ... determine public attitudes toward the practice of using the ... University study will help drive public policy decisions and ... known as the Michigan BioTrust, said Ann Mongoven, an ...
... new insights into whys and hows of the famous caste ... bee larvae destined for royalty and the masses for worker ... bees and worker bees appears in ACS,s Journal of ... work of scientists from China and Ethiopia) note that despite ...
... Global emissions of carbon dioxide (CO2) the main ... between 1990 and 2010, and reached an all-time high ... nuclear energy and the growing contribution of renewable energy ... power and transport, which is strongest in developing countries. ...
Cached Biology News:MSU engages public on using newborn blood spots for research 2Steep increase in global CO2 emissions despite reductions by industrialized countries 2Steep increase in global CO2 emissions despite reductions by industrialized countries 3
...
... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... pAcAB4 vector is a 10.0 kb Autographa ... two,copies of the AcNPV polyhedrin promoter and ... first p10,promoter is a Sma I cloning ... Upstream of this,an inverted polyhedrin promoter has ...
Biology Products: